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Abstract 30 
Objectives: In 2013, the Follow-up and Active Surveillance of Trivalent Influenza Vaccine in 31 
Mums (FASTMum) program began using short message service (SMS) to collect adverse 32 
event information in pregnant women who recently received trivalent influenza vaccine (TIV). 33 
This study was designed to compare data collected via SMS and telephone for the purposes 34 
of monitoring vaccine safety. 35 
Methods: 344 women who received TIV were randomly assigned to a telephone interview 36 
group. They were telephoned seven days post-vaccination and administered a standard 37 
survey soliciting any adverse events following immunisation (AEFI) they experienced. They 38 
were matched by brand of vaccine, age group, and residence to 344 women who were sent 39 
a SMS seven days post-vaccination. The SMS solicited similar information. AEFI reported by 40 
SMS and telephone interview were compared by calculating risk ratios. 41 
Results: Response rate was higher to SMS compared to telephone interview (90.1% vs. 42 
63.9%). Women who were surveyed by SMS were significantly less likely to report an AEFI 43 
compared to women who were surveyed by telephone (RR: 0.41; 95% CI: 0.29-0.59). The 44 
greatest discrepancies between SMS and telephone interview were for self-reported 45 
injection site reactions (3.1% vs. 16.8%) and unsolicited (or “other”) events (11.4% vs. 46 
4.1%). Data collected by SMS was significantly timelier.  47 
Conclusions: Data collection by SMS results in significantly improved response rates and 48 
timeliness of vaccine safety data. Systems which incorporate SMS could be used to more 49 
rapidly detect safety signals and promote more rapid public health response to vaccine 50 
quality issues. 51 
 52 
 53 
 54 
 55 
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1. Introduction 57 
Vaccine safety programs are fundamental for promoting vaccine uptake in the community, 58 
since any perceived vaccine safety issue can undermine confidence in vaccination [1]. 59 
Misperceptions of vaccine safety are a common contributor to low immunisation rates [2-6]. 60 
For example, in Western Australia an unexpected spike in adverse events following trivalent 61 
influenza vaccination in children in 2010 resulted in an 84% reduction in influenza vaccine 62 
uptake in young children [7, 8]. This example serves as a reminder of the necessity of 63 
vigilant vaccine safety programs and the importance of rapid signal response. Further, 64 
influenza vaccines continually change in antigenic composition to accommodate shifting 65 
strains, but are not considered new vaccines and do not undergo the same efficacy and 66 
safety studies as new vaccines [9]. Timely collection of vaccine safety data is necessary in 67 
order to identify early warning signals and ensure vaccine quality.  68 
 69 
Some vaccine safety surveillance programs incorporate short message service (SMS) 70 
communication to monitor adverse events following immunisation (AEFI) details in near real-71 
time [10-13]. While such methods offer rapid data collection and dissemination of results, to 72 
date, no study has investigated the potential differences between SMS and telephone 73 
interview data collection methods.  This study compares SMS with telephone interviews for 74 
the purpose of performing vaccine safety surveillance in terms of a) response rate; b) 75 
adverse events reported; and c) the timeliness of obtaining data.  76 
 77 
2. Methods 78 
The Follow-up and Active Surveillance of Trivalent influenza vaccine in Mums (FASTMum) 79 
program has monitored the safety of pregnant women who receive inactivated TIV in Western 80 
Australia since 2012 [14]. Historically, data collection has relied on telephone interviews of 81 
vaccinated pregnant women; however, in 2013, SMS was introduced as a method of collecting 82 
AEFI information [11]. In 2014, a subset of 344 women were followed up by telephone 83 
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interview for comparison purposes. All follow-up occurred between 16 March and 22 May 84 
2014.  85 
 86 
2.1 Sample selection 87 
In Western Australia, immunisation providers report details of antenatal influenza 88 
immunisations to the Western Australia Department of Health (WA Health) by submitting 89 
immunisation reports which include the vaccination date, vaccine brand and batch number, 90 
and mobile phone number of the vaccinee [11]. At the time of vaccination, women are asked 91 
to indicate on these reports whether they give permission to be contacted by telephone or 92 
SMS by WA Health for the purposes of monitoring vaccine safety [11]. During the study time 93 
period, 2,011 women were reported to WA Health as receiving TIV and consented to follow-94 
up. A random sample of women (n=344) was selected to receive a telephone interview seven 95 
days post-vaccination using a random number generator. The remaining 1,667 women were 96 
followed up by SMS seven days post-vaccination. Of these 1,667 women, 344 were 97 
individually matched by brand of TIV received, age group (18-29 years, 30-39 years, or 40-45 98 
years), and residence (metropolitan or rural) to a sample of women who received the same 99 
questions via SMS. The sample size was powered to detect a ±4% difference between groups 100 
at β=.80. 101 
 102 
2.2 Data collection 103 
For participants in the SMS-group, a text message was sent seven days following 104 
vaccination asking: 105 
“In the week since your vaccination, did you experience any reaction, fever, or 106 
illness? Please reply Y or N.” 107 
Women who did not reply were sent a second message within 24 hours with the same text. 108 
Women who replied “yes” to either message were sent an additional SMS asking them to 109 
complete a five minute survey on their mobile phone. Women who did not complete the 110 
survey were telephoned to ask about details related to their reaction. The survey asked if 111 
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they had experienced any of the following:  fever, headache, fatigue, rash, swelling, redness, 112 
or pain at the injection site, rigors, or convulsions. Women could make multiple selections 113 
and were permitted to record additional events in a free text field. At the end of the survey, 114 
women were asked if they had visited any doctor, medical centre, after hours clinic, or 115 
emergency department regarding their reaction.  116 
 117 
For participants in the telephone-group, a research nurse telephoned the mobile phone of 118 
the participant seven days post-vaccination. No SMS messages were sent to women in this 119 
group, and all questions in the telephone interview were identical to those of the mobile 120 
phone survey. Women were asked by telephone whether they experienced any reaction and 121 
women who replied affirmatively were asked about details related to the reaction. Women 122 
who did not respond to telephone interview were telephoned again 24 hours later, until a 123 
maximum of three contact attempts were made. 124 
 125 
2.4 Outcomes measured 126 
We were interested in comparing the two methods of collecting vaccine safety data in terms 127 
of response rate, reactions reported, and timeliness of the data collection. We defined 128 
‘response rate’ as the proportion of participants who returned a text message in the SMS-129 
group or answered a telephone call in the telephone-group. The proportion of women who 130 
experienced each reaction included on the surveys was calculated and compared between 131 
groups. We also compared response rate to SMS and telephone interview by 132 
sociodemographic characteristics. We calculated the time required to collect completed 133 
adverse event information for both data collection methods.  134 
 135 
2.5 Statistical analysis 136 
Data were analysed using SAS version 9.3 (SAS Institute Inc, Sydney, NSW, Australia). 137 
Response rates to SMS and telephone interview were compared by sociodemographic 138 
subgroups using Cochran Mantel-Haenszel (CMH) chi square tests. The response rates to 139 
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SMS versus telephone interview were compared overall and by sociodemographic factors by 140 
calculating risk ratios (α=.05). Risk ratios were also used to compare the number of women 141 
who reported each event by SMS and telephone interview. Independent sample t-tests were 142 
used to compare the mean time (in days) required to collect complete AEFI data by SMS 143 
and telephone interview.  144 
 145 
3 Results 146 
A total of 688 women who had received trivalent influenza vaccine between 9 March and 15 147 
May 2014 were followed up: 344 by SMS and 344 by telephone interview (Figure 1). The 148 
majority of women resided in the metropolitan area (84.6%), were non-Aboriginal (95.8%), 149 
were in their second or third trimester of pregnancy (80.0%), were between 30 and 45 years 150 
of age (62.2%) and were in the top 60% of socioeconomic levels (86.1%). Women 151 
commonly received either Vaxigrip® (40.7%) or Fluvax® (49.1%); 8.3% received Fluarix®, 152 
and 1.9% received other brands. There were no demographic or vaccination differences 153 
identified between SMS and telephone groups (p>0.05).  154 
 155 
3.1  Response Rate 156 
A total of 310 (90.1%) of women replied to SMS (Figure 1). Response to SMS was lower in 157 
Aboriginal women compared to non-Aboriginal women (66.7% vs. 92.2%; CMH=9.22, 158 
p<0.01). No difference was observed in response to SMS by residence, trimester of 159 
pregnancy, socioeconomic status, or age group (p<0.05). A total of 220 (66.7%) of women 160 
responded to telephone interview. Response to telephone was significantly lower in women 161 
who resided outside the metropolitan area compared to those within the metropolitan area 162 
(78.5% vs. 88.3%; CMH: 7.06,  p<0.01). No difference was observed in response to 163 
telephone interview by Aboriginal status, trimester of pregnancy, socioeconomic status, or 164 
age group (p>0.05).  165 
 166 
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Overall, response rate was significantly higher with SMS than telephone interviews (90.1% 167 
vs 66.7%, p<0.01)(Table 1). Women were 40% more likely to reply to SMS compared to 168 
telephone interview (RR: 1.41, 95% CI: 1.29-1.54). This association was consistent across 169 
sociodemographic groups, with the exception of Aboriginal women, women aged 40-45 170 
years and women in the second quintile of socioeconomic status (p>0.05).   171 
 172 
On average, 1.4 telephone calls were required to complete a telephone interview with one 173 
woman; 146 (66.4%) of women replied to the first telephone call. The majority of women who 174 
replied to SMS, replied to the first message (n=277, 89.3%). Of the 38 women who replied to 175 
the SMS indicating they had experienced an AEFI, 23 (60.5%) women provided information 176 
related to the event: 10 (43.5%) by mobile phone survey and 13 (56.5%) had to be 177 
telephoned. The remaining 15 women who indicated they experienced a reaction could not 178 
be reached by either telephone interview or SMS.  179 
 180 
3.2  Events reported 181 
Women in the SMS-group were 59% less likely to report an AEFI compared to women in the 182 
telephone-group (RR 0.41; 95% CI 0.29-0.59) (Table 2). When we compared the events 183 
reported by women who experienced an AEFI, women in the SMS-group were 81% less 184 
likely (RR 0.18, 95% CI 0.09-0.37) to report a local reaction and 64% less likely (RR: 0.36, 185 
95% CI 0.05-0.70) to report events not included in the survey (Table 2). Women were just as 186 
likely to report fever, headache, fatigue, vomiting, rash, or rigors by SMS or telephone, and 187 
no women reported convulsions. Women were just as likely to report having sought medical 188 
care for their AEFI by SMS and telephone (RR: 0.45; 95% CI: 0.11-1.85).  189 
 190 
3.3  Timeliness of data 191 
Collection of AEFI details from SMS participants required significantly less time than 192 
telephone participants (Figure 2); 95.6% of women in the SMS-group reported complete 193 
AEFI details within 24 hours of follow-up, compared to 16.6% of women in the telephone-194 
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group. On average, complete AEFI information was obtained from women in the SMS-group 195 
within 2.4 hours (95% CI: 2.4-4.8 hours) of follow-up, whereas information was obtained 196 
from women in the telephone-group within 2.7 days (95% CI: 2.5-3.0 days)(t: 20.3, p<0.01). 197 
The time required to collect information was similar for women who experienced a reaction 198 
as those who did not experience a reaction (1.6 days vs 1.3 days, t: -1.03, p=0.30).  199 
 200 
4 Discussion 201 
To our knowledge, this is the first study specifically designed to directly compare SMS with 202 
telephone interview for the purpose of AEFI surveillance. Based on our results, an SMS-203 
based adverse event monitoring program would detect a similar rate of medically-attended 204 
adverse events as a telephone-based system. Data collection by SMS was significantly 205 
more rapid and associated with improved response rates over telephone interviews. These 206 
results indicate SMS could be used to implement an AEFI monitoring program with the 207 
capability for rapid response to safety signals.  208 
 209 
Previous observational studies support our findings, in that response to SMS often exceeds 210 
80% [10, 11] and adverse event information can vary when collected by SMS and telephone 211 
interview, which is consistent with previous observational studies [11]. Internationally, there 212 
is growing evidence supporting the feasibility of SMS as a method of data collection. In the 213 
United States, researchers successfully used SMS to monitor the reactogenicity of trivalent 214 
influenza vaccine in children over a seven day period [15]. In Sweden, Bexelius et al. [16] 215 
compared SMS to standardised telephone interviews for administering three survey 216 
questions related to influenza and influenza vaccination. Vaccination data collected by SMS 217 
was statistically similar to data collected by telephone interview. A number of other public 218 
health systems have further demonstrated the utility of SMS for data collection, including 219 
collection of immunisation status [16], asthma symptoms [17], irritable bowel syndrome 220 
symptoms [18], Ebolavirus symptoms [19], and pain outcomes [20]. 221 
 222 
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Our results indicate that SMS can be used as a valuable tool for signal detection; however, 223 
some of our findings suggest there are limitations of SMS for AEFI monitoring. First, 224 
although 90% of women replied to the initial SMS, 56.5% of women who reported an AEFI 225 
via SMS did not respond to the follow-up SMS and had to be telephoned to collect details of 226 
the event. These results indicate SMS may not be a complete solution to AEFI information 227 
collection. Second, there were some distinct differences in the events reported by SMS 228 
compared to telephone. Women surveyed by telephone were more likely to report any 229 
adverse event, which can largely be attributed to their increased reporting of injection site 230 
reactions. Although not designed to compare the different methods of AEFI data collection, a 231 
similar previous investigation found that women followed up by telephone interview were four 232 
times as likely to report a local reaction and nearly twice as likely to report a systemic 233 
reaction [11], similar to our results. These findings may suggest that SMS is not suitable for 234 
determining an accurate proportion of vaccinees who experience mild, common events, but 235 
would instead be suited for monitoring for changes in the safety profile of a vaccine. 236 
Regardless of these shortfalls, SMS would detect a safety signal more rapidly compared to 237 
telephone interviews. 238 
 239 
While this study provides valuable information which can be used to improve vaccine safety 240 
monitoring programs, there were several limitations to our investigation. Due to the 241 
population of the routine vaccine safety monitoring program in Western Australia, our sample 242 
was restricted to pregnant females and our results may not necessarily apply to other 243 
demographic groups. The events reported in this study were self-reported and had not been 244 
verified by a health professional. Discrepancies between the rates of AEFI reported by SMS 245 
and by telephone interview may be due to response bias. It is plausible that the method of 246 
inquiry affected the probability for a vaccinee to recall and report an AEFI. Additional 247 
research where reported AEFI are medically verified could provide further information on the 248 
use of SMS for data collection. Finally, unlike the SMS group, only 17% of the telephone 249 
group were successfully contacted at seven days post-vaccination. As a result, the variation 250 
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in time required to follow-up by telephone compared to SMS may have biased our results. 251 
However, among the women who were successfully contacted by telephone within seven 252 
days, 37% reported a reaction, similar to the proportion of all women who were followed up 253 
by telephone interview. This indicates that variation in follow-up time is unlikely to be the 254 
reason for the differences in AEFI observed in our study. 255 
 256 
4.1 Conclusions 257 
We compared the use of SMS and telephone interviews for the purposes of collecting AEFI 258 
information. Our results show that SMS can be used to improve existing vaccine safety 259 
surveillance systems, with certain caveats. Evaluations such as ours are important for 260 
informing public health initiatives, considering the current interest in transitioning surveillance 261 
systems to mobile phone technology [10-12, 18, 19]. Systems which incorporate SMS as a 262 
method of data collection have the potential to more rapidly detect a safety signals and 263 
facilitate quick response to identified vaccine quality issues and warrant further exploration.  264 
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Figure 1 title: 
Figure 1. Adverse event following influenza immunisation monitoring by SMS and telephone 
– Western Australia, Australia, March-May, 2014. 
Figure 1 footnotes:  
SMS, short message service 
 
Figure 2 title: 
Figure 2. Number of follow-up days, by method of adverse event reporting – Western 
Australia, Australia, March – May, 2014. 
Figure 2 footnotes: 
SMS, short message service 
AEFI, adverse event following immunisation 
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